Non Hodgkin Lymphoma Clinical Trial

Clinical Trial Finder Non Hodgkin Lymphoma Trials

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

See Locations Near You

Summary

This is a A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

View Full Description

Full Description

This clinical trial is for men and women ages 18 and older with follicular lymphoma with detectable BCL2-t or mantle cell lymphoma with presence of cyclin D1 overexpression (can be newly diagnosed or relapsed). The objective of this study is to assess the possibility of treating follicular lymphoma and mantle cell lymphoma patients with ribavirin and using cell free DNA (cfDNA) for BCL2-t and cyclin D1 extracted from peripheral blood to measure treatment effect.

Clinical trials of ribavirin have been conducted in relapsed and refractory acute myeloid leukemia (AML). Ribavirin, an antiviral agent with established doses, has resulted in the regression of the tumor.

Ribavirin 1000 mg will be administered orally twice daily continuously for 28-day cycles.
Patients will be followed for up to 7 months.
Will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of histologically confirmed follicular lymphoma with detectable BCL2-t or mantle cell lymphoma with presence of cyclin D1 overexpression (can be newly diagnosed or relapsed)
Measurable disease (At least one tumor mass > 1 cm in diameter)

Low tumor burden:

No individual masses larger than 6 cm in diameter
No more than three masses larger than 3 cm in diameter
No lymphoma-related symptoms
The treating physician does not feel that treatment with chemotherapy is indicated
ECOG performance status of 0-2

Adequate bone marrow and end organ function:

i. ANC≥1500/mm3, hemoglobin≥10 g/dL, platelet≥100/mm3 ii. CrCL≥50 mL/min by Cockcroff Gault calculation

Exclusion Criteria:

Indication for treatment of lymphoma including large tumor burden or symptomatic disease
Pregnancy or men whose female partners are pregnant
Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
Significant or unstable cardiac disease
Hemoglobinopathy (thalassemia or sickle cell disease)

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Early Phase 1

Estimated Enrollment:

3

Study ID:

NCT03585725

Recruitment Status:

Terminated

Sponsor:

Weill Medical College of Cornell University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Weill Cornell Medicine
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Early Phase 1

Estimated Enrollment:

3

Study ID:

NCT03585725

Recruitment Status:

Terminated

Sponsor:


Weill Medical College of Cornell University

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Clinical Trials Test State-of-the-Art Cancer Treatments
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider